Triphenyl-2h-tetrazolium chloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: Triphenyl-2h-tetrazolium chloride
• 英文别名: 1,2,5-triphenyltetrazol-1-ium;chloride
• 化学式: C19H15ClN4
• 分子量: 334.8
• InChiKey: CPWCKGMTKBLVHZ-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  0.21
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  34.6
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP)<br/>[FR] PETITES MOLÉCULES INHIBITRICES DU PORE DE TRANSITION DE PERMÉABILITÉ MITOCHONDRIALE (MTPTP)
  申请人：UNIV KANSAS

  公开号：WO2016073633A1

  公开（公告）日：2016-05-12

  The present technology relates to compounds of any one of Formula I, II, IIa, III, IV, and/or V as described herein and their tautomers and/or pharmaceutically acceptable salts, compositions, and methods of uses thereof.

  目前的技术涉及到本文描述的任一式I、II、IIa、III、IV和/或V的化合物，以及它们的互变异构体和/或药用盐、组合物以及使用方法。
• [EN] COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISEASES<br/>[FR] COMPOSES POUR TRAITEMENT DES MALADIES CARDIO-VASCULAIRES
  申请人：PFIZER PROD INC

  公开号：WO2005079803A1

  公开（公告）日：2005-09-01

  Pharmaceutical compositions containing sodium-hydrogen exchanger type 1 (NHE-1) inhibitors in combination with Ca 2+ overload inhibitors, and the use of such combination inhibitors to treat, for example, cardiovascular disease, such as ischemia, particularly, perioperative myocardial ischemic injury in mammals, including humans, are disclosed.

  含有钠-氢交换型1（NHE-1）抑制剂与Ca2+超载抑制剂的药物组合，以及利用这种组合抑制剂治疗心血管疾病（如缺血），特别是哺乳动物（包括人类）中的围手术期心肌缺血性损伤的用途被披露。
• SUBSTITUTED IMIDAZOPYRIDINE AMIDES AND USE THEREOF
  申请人：Bayer Aktiengesellschaft

  公开号：US20200339567A1

  公开（公告）日：2020-10-29

  The present application relates to novel substituted imidazopyridine amides of the formula (I), to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prophylaxis of diseases and to their use for the production of medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular, neurological and central nervous as well as metabolic disorders.

  本申请涉及新型取代咪唑吡啶酰胺的化合物（I）的制备方法，它们的使用，单独或组合用于治疗和/或预防疾病，以及它们用于生产用于治疗和/或预防疾病的药物，特别是用于治疗和/或预防心血管、神经系统和中枢神经以及代谢紊乱疾病。
• Inhibitors of human glycogen phosphorylase
  申请人：Pfizer Products Inc.

  公开号：EP0978279A1

  公开（公告）日：2000-02-09

  The present invention is directed to a novel binding site for a glycogen phosphorylase inhibitor found within a glycogen phosphorylase enzyme. The novel binding site allows the design novel of glycogen phosphorylase inhibitors.

  本发明涉及一种在糖原磷酸化酶酶内发现的新型糖原磷酸化酶抑制剂结合位点。该新型结合位点使得能够设计新型的糖原磷酸化酶抑制剂。
• Water-Soluble Derivatives and Prodrugs of Acacetin and Methods of Making and Using Thereof
  申请人：Shanghai Institute of Pharmaceutical Industry

  公开号：US20150218193A1

  公开（公告）日：2015-08-06

  Water-soluble derivatives and/or prodrugs of acacetin are described herein. The compounds can be used as cardioprotection agents against myocardial infarction induced by ischemia-reperfusion. In one embodiment the compounds are used to treat ischemic cardiac diseases. In the preferred embodiment, the compounds are used to treat and/or prevent myocardial infarction in humans.

  水溶性阿克塞丁衍生物和/或前药在本发明中有所描述。这些化合物可用作针对由缺血-再灌注引起的心肌梗死的护心剂。在一个实施例中，这些化合物用于治疗缺血性心脏病。在优选的实施例中，这些化合物用于治疗和/或预防人类的心肌梗死。